dc.contributor.author
Karawajew, Leonid
dc.contributor.author
Dworzak, Michael
dc.contributor.author
Ratei, Richard
dc.contributor.author
Rhein, Peter
dc.contributor.author
Gaipa, Giuseppe
dc.contributor.author
Buldini, Barbara
dc.contributor.author
Basso, Giuseppe
dc.contributor.author
Hrusak, Ondrej
dc.contributor.author
Ludwig, Wolf-Dieter
dc.contributor.author
Henze, Günter
dc.contributor.author
Seeger, Karl
dc.contributor.author
Stackelberg, Arend von
dc.contributor.author
Mejstrikova, Ester
dc.contributor.author
Eckert, Cornelia
dc.date.accessioned
2018-06-08T03:45:42Z
dc.date.available
2015-10-16T12:20:47.917Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/15875
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-20062
dc.description.abstract
Multiparametric flow cytometry is an alternative approach to the polymerase
chain reaction method for evaluating minimal residual disease in treatment
protocols for primary acute lymphoblastic leukemia. Given considerable
differences between primary and relapsed acute lymphoblastic leukemia
treatment regimens, flow cytometric assessment of minimal residual disease in
relapsed leukemia requires an independent comprehensive investigation. In the
present study we addressed evaluation of minimal residual disease by flow
cytometry in the clinical trial for childhood relapsed acute lymphoblastic
leukemia using eight-color flow cytometry. The major challenge of the study
was to reliably identify low amounts of residual leukemic cells against the
complex background of regeneration, characteristic of follow-up samples during
relapse treatment. In a prospective study of 263 follow-up bone marrow samples
from 122 patients with B-cell precursor acute lymphoblastic leukemia, we
tested various B-cell markers, adapted the antibody panel to the treatment
protocol, and evaluated its performance by a blinded parallel comparison with
the polymerase chain reaction data. The resulting eight-color single-tube
panel showed a consistently high overall concordance (P<0.001) and, under
optimal conditions, sensitivity similar to that of the reference polymerase
chain reaction method. Overall, evaluation of minimal residual disease by flow
cytometry can be successfully integrated into the clinical management of
relapsed childhood acute lymphoblastic leukemia either as complementary to the
polymerase chain reaction or as an independent risk stratification tool. ALL-
REZ BFM 2002 clinical trial information: NCT00114348
en
dc.rights.uri
http://creativecommons.org/licenses/by/3.0/de/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Minimal residual disease analysis by eight-color flow cytometry in relapsed
childhood acute lymphoblastic leukemia
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Haematologica. - 100 (2015), 7, Artikel Nr. 935
dcterms.bibliographicCitation.doi
10.3324/haematol.2014.116707
dcterms.bibliographicCitation.url
http://www.haematologica.org/content/100/7/935
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000023334
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publizieren.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000005565
dcterms.accessRights.openaire
open access